Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Ceptur Therapeutics, a US-based targeted oligonucleotide therapeutics developer based on research at Rutgers University, launched yesterday with $75m in series A capital co-led by Qiming Venture Partners and VenBio Partners, with commitments from pharmaceutical firm Bristol Myers Squibb, Perceptive Advisors’ Xontogeny Venture Fund, Janus Henderson, Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. Ceptur had raised $6.2m in seed financing in August 2020, according to a regulatory filing, with Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners identified…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
